BioAge Labs (NASDAQ:BIOA) Upgraded to “Strong-Buy” at Roth Mkm

Roth Mkm upgraded shares of BioAge Labs (NASDAQ:BIOA) to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.

Other analysts have also recently issued research reports about the company. BTIG Research assumed coverage on BioAge Labs in a research report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price objective for the company. Piper Sandler assumed coverage on BioAge Labs in a research report on Tuesday, January 27th. They set an “overweight” rating for the company. Morgan Stanley set a $23.00 price objective on BioAge Labs in a research report on Wednesday, February 4th. Needham & Company LLC assumed coverage on BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 price objective for the company. Finally, Citigroup lifted their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.50.

BioAge Labs Trading Up 4.6%

BioAge Labs stock opened at $16.95 on Wednesday. The stock has a market cap of $753.43 million, a PE ratio of -7.06 and a beta of 0.99. The stock has a 50-day moving average price of $17.54 and a 200 day moving average price of $16.37. BioAge Labs has a 52 week low of $3.79 and a 52 week high of $24.00.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. On average, equities analysts predict that BioAge Labs will post -2.59 EPS for the current year.

Institutional Trading of BioAge Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Stempoint Capital LP purchased a new stake in BioAge Labs in the 1st quarter valued at about $5,923,000. Janus Henderson Group PLC grew its holdings in BioAge Labs by 411.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after buying an additional 1,685,063 shares during the period. Quantinno Capital Management LP purchased a new stake in BioAge Labs in the 1st quarter valued at about $404,000. Octagon Capital Advisors LP grew its holdings in BioAge Labs by 9.4% in the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after buying an additional 150,000 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in BioAge Labs by 653.2% in the 1st quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock valued at $2,424,000 after buying an additional 120,188 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.